- Our World
- Our Business
- Life at Lupin
- Global Sites
The NDDD team has develoed a pipeline of highly differentiated and innovative new chemical entities in the therapeutic areas of Oncology, Immunology and Metabolic disorders.
Current Clinical Programs
Endocrine: Clinical Phase-I study successfully completed in Europe and the product was found to be safe and well tolerated. A Phase-II study has been initiated in India for Chronic Kidney Disease patients on dialysis and also for those not on dialysis.
Oncology: Clinical Phase-I study successfully completed in Europe on terminally-ill patients (Lung Cancer, Melanoma & Colon Cancer). A Phase-II study has commenced in India for treating a refractory type of Lung cancer which has RAS mutations for which no treatment exists worldwide.